comparemela.com

Brad Canino News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Celcuity Inc (NASDAQ:CELC) Q1 2024 Earnings Call Transcript

Operator: Good afternoon, ladies and gentlemen. And welcome the Celcuity First Quarter 2024 Financial Results Conference call. At this time, all lines are in a listen-only mode.

San antonioUnited statesVicky hahneTara bancroftGil blumBrian sullivanMaria yonkoskiEldon mayerIgor gorbatchevskyMaury raycroftBrad caninoCelcuity incNeedham companyCall transcript mayCelcuity first quarterResults conference

Kymera Therapeutics, Inc (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript

Operator: Good day, and welcome to the Kymera Therapeutics First Quarter 2024 Results Conference Call. All participants will be in the listen-only mode.

United statesSan diegoEllie merleJared gollobDeric josephThomas smithKalpit patelDivya raoNat charoensookNello mainolfiVikram purohitAndy chenBrad caninoJustine koenigsbergMichael schmidtDerek archila

Summit Therapeutics Inc (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript

Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06.

United statesBob dugganAllen yangBrad caninoBradley caninoManmeet soniMostafa ronaghiCarter gouldDave gancarzMaky zanganehUs national cancer instituteEuropean organization for researchSummit therapeutics incTeam summitAmerican association of cancer researchAmerican society of clinical oncology

Why Summit Therapeutics Stock Crushed the Market This Week

The company was a standout in the biotech field, rising by nearly 23% over the period.

United statesStifel brad caninoSummit therapeuticsBrad caninoNorth americaMotley fool stock advisorStock advisorShare priceSummit therapeuticsStock advisorLung cancerBrad canino

Why Summit Therapeutics Stock Crushed the Market This Week

The company was a standout in the biotech field, rising by nearly 23% over the period.

United statesStifel brad caninoSummit therapeuticsBrad caninoNorth america

vimarsana © 2020. All Rights Reserved.